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Summary We examined the prognostic value of early serum CA125 assay in 58 patients with advanced
epithelial ovarian cancer together with residual disease, age, tumour grade, performance status, and the
presence of ascites or adhesions at primary surgery. CA125 was a highly significant predictor of both
progression free and overall survival after the first cycle and throughout primary chemotherapy. After the first
cycle, CA125 was by far the most significant predictor of progression free survival (P<0.0005). At this time,
CA125 was a highly significant predictor of survival (P<0.005), but did not add to performance status
(P<0.001) in multivariate analysis. We were able to identify three statistically-distinct prognostic groups.
Patients in the upper quartile, with CAl 25 levels greater than 450 U ml -, had a very poor median survival of
7 months. Patients in the lower quartile, with CA125 levels less than 55 U ml-I had a good median survival of
23 months. Those in the two interquartile groups, who had CA125 levels ranging from 58-221 U ml-' and
228-434 U ml-', had relatively intermediate median survival times of 16 months and 15 months respectively.
Although CA125 levels provided significant prognostic information, in the majority of patients CA125 merely
confirmed overall clinical impression.
A number of factors of prognostic importance have been
identified in patients with epithelial ovarian cancer (EOC),
including stage, age, tumour grade, histological type, volume
of residual disease, site of metastases, volume of ascites,
performance status, oestrogen and progesterone receptor
status, psammoma body content and ploidy. All published
studies addressing this issue, however, agree upon the impor-
tance of residual disease (Webb, 1989), first quantitated by
Griffiths (1975), whereas the other factors vary in signi-
ficance.
Pre-operative CA125 levels (Lavin et al., 1987; Vergote et
al., 1987; Rosen et al., 1990), post-operative levels (Redman
et al., 1990; Rosen et al., 1990), absolute levels after one
(Fisken et al., 1991), two (Sevelda et al., 1989; Redman et al.,
1990), and three (Lavin et al., 1987) cycles of primary
chemotherapy, the half-life (Van der Burg et al., 1988; Haw-
kins et al., 1989), and rate of fall (Rustin et al., 1989) after
the first cycle of chemotherapy have all been advocated as
useful prognostic indicators. Although the prognostic signi-
ficance of early CA125 assay has been reported by several
authors, there is no consensus yet regarding the most useful
time to measure CA125.
CA125 is of undisputed value in monitoring EOC patients
(for review see Jacobs & Bast, 1989), however, clarification of
its prognostic value is essential if CA125 is to influence early
treatment decisions. Studies to date have considered different
combinations of prognostic factors and have found CA125
statistically significant at different times during treatment.
Moreover, different endpoints have been reported, with a few
studies addressing the value of CA125 for predicting survival.
Prognostic factors also vary with stage (Swenerton et al.,
1985) although they have mostly been evaluated in patients
with advanced disease as a result of the high incidence of this
group of patients. Patients with 'advanced' EOC, however,
represent a heterogeneous group, with 5 year survival varying
from 7% to 62% (Marsoni et al., 1990). The knowledge that
these patients may be assigned to distinct prognostic groups
may serve clinicians as a guideline for a more accurate
estimate of the trade-off between toxicity and survival offered
by alternative forms of chemotherapy. Such information is
desirable as early during treatment as possible, to avoid
unnecessary toxicity in patients with a poor outlook and to
ensure that patients with a good outlook receive optimal
therapy.
We examined the prognostic value of CA125 together with
post-operative residual disease, tumour grade, age at diag-
nosis, performance status, and the presence or absence of
ascites and adhesions at surgery. The value of each of these
factors in predicting both progression free and overall sur-
vival was assessed in the immediate post-operative period
and before each cycle of primary chemotherapy in patients
with stages III and IV disease.
Patients and samples
Blood samples were collected from April 1984 to July 1989
from patients attending the Royal Infirmary and Western
General Hospital in Edinburgh. The blood was separated by
centrifugation at 1500 g for 10 min at room temperature and
the serum was stored in aliquots at - 20'C until assay. One
hundred and twenty-seven patients had blood samples taken
during the post-operative period and throughout primary
chemotherapy. Samples were obtained immediately prior to
administration of chemotherapy. The first sample was
obtained a median 18 days after primary laparotomy. Not all
patients had samples taken before each cycle, therefore
different patient groups were assessed at each time point.
Consequently, the significance levels quoted at different times
are not directly comparable. The group with samples taken
after the first cycle of therapy will be examined in more detail
later.
CA125 assay
CA125 was assayed using the CIS IRMA according to
manufacturer's instructions. A cut-off value of 35 U ml was
used, as established by Bast et al. (1983).
Statistics
A database consisting of the EOC patients' case histories and
serial CA125 levels was developed at Unilever Research,
Colworth, UK (Fisken, 1991). The database was constructed
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using the URL Colworth VAX/VMS mainframe computer
system, and statistical analysis performed using the SAS
(Statistical Analysis System) software package. All marker
data were logarithmically transformed for statistical analysis.
Using the SAS Lifetest procedure (SAS/STAT Users Guide,
1990), univariate and multivariate analysis of prognostic fac-
tors were performed using the Wilcoxon test. Stratification of
the data was not undertaken for the multivariate analysis; all
prognostic indicators were included as covariates for sim-
ultaneous testing. Progression free survival and survival pro-
babilities were calculated using the Kaplan-Meier method
(Kaplan & Meier, 1958) and differences between curves
tested using the Log rank test (Peto et al., 1977). In all
analyses CA125 and age were treated as continuous vari-
ables, whereas performance status, residual disease, ascites,
adhesions and tumour grade were treated as categorised
variables.
Results
Factors influencing progressionfree survival
Table I shows the results of univariate analysis of prognostic
factors for progression free survival before each cycle of
chemotherapy. Tumour grade, and the presence or absence
of ascites and adhesions were not significant at any time. In
the immediate post-operative period, age was the most
significant factor (P<0.0005), and performance status
(P<0.05) added to age in multivariate analysis. After one
cycle of chemotherapy, CA125 was the most significant
predictor of progression free survival (P<0.0005); no other
factor added significantly to CA125 in multivariate analysis.
CA125 remained highly significant throughout first-line
therapy, although the volume of residual disease was more
significant than CA125 after two cycles of therapy.
Factors influencing survival
Table II shows the results of univariate analysis of prognostic
factors for survival before each cycle of chemotherapy.
Tumour grade was not significant at any time. The most
significant predictor of survival, like progression free sur-
vival, in the immediate post-operative period was age
(P<0.002). Performance status (P<0.05) added to age in
multivariate analysis at this time. CA125 (P<0.005) and
performance status (P<0.001) were the most significant
predictors of survival after one cycle of chemotherapy, but
CA125 did not add to performance status in multivariate
analysis. CA125, however, remained the most significant
predictor of survival throughout first-line chemotherapy.
The value ofCA125 after one cycle ofprimary chemotherapy
CA125 was not a significant predictor of either progression
free or overall survival in the immediate post-operative
period, but after one cycle remained significant for both
progression free and overall survival throughout primary
chemotherapy. Patients with CA125 levels of >50OUml-I
after one cycle of chemotherapy had a very poor survival.
They represented the upper quartile of the total group. Con-
sequently, the total patient group (n = 57) was divided into
quartiles based on CA125 levels to determine if further prog-
nostic groups could be identified on this basis. Table III
shows the disease characteristics of patients in each quartile.
Progression free and overall survival curves were plotted for
each quartile (groups A, B, C and D). It was only possible to
obtain dates of progression for 38 of the 57 patients who had
CA125 assayed at this time. Table IV shows the treatment
regimes given to patients in each quartile, their responses and
reasons for stopping treatment. The number of patients in
each category who had progression dates are shown in
brackets.
Prediction ofprogressionfree survival with CA125
Figure 1 shows the progression free survival curves for each
group. The difference between the curves was significant
(X2 = 9.48, df = 3, P<0.02). Three prognostic groups can be
identified. Patients in group A had relatively poor median
progression free survival of 4.5 months, patients in groups B
and C had intermediate progression free survival of 8.5 and
12.0 months respectively. Those in group D had good
median progression free survival of 19.0 months. Patients in
group A had significantly poorer progression free survival
than those in groups B (X2 = 4.27, df = 1, P<0.05), group C
(X2 = 4.72, df= 1, P<0.05), and group D (X2 = 8.33, df= 1,
P<0.005). There was no significant difference in progression
free survival between patients in groups B and C. Patients in
group D had significantly better progression free survival
than those in group A (X2 = 8.33, df= 1, P<0.005), group B
Table I Factors influencing progression free survival. Table I shows the results of univariate
analysis of prognostic factors for progression free survival before each cycle of
chemotherapy
P value (X2) before cycle number
1 2 3 4 5 6
Prognosticfactor (n = 53) (n = 57) (n = 52) (n = 49) (n = 43) (n = 33)
Residual disease 0.005 0.05 0.005 NS 0.002 0.05
Age 0.0005 0.01 NS NS NS NS
Performance status 0.005 0.005 NS 0.05 NS NS
CA125 NS 0.0005 0.01 0.0005 0.0005 0.05
NS = not significant
Table II Factors influencing survival. Table II shows the results of univariate analysis of
prognostic factors for survival before each cycle of chemotherapy
P value (X2) before cycle number
1 2 3 4 S 6
Prognosticfactor (n = 53) (n = 57) (n = 52) (n = 49) (n = 43) (n = 33)
Residual disease 0.01 0.02 0.05 NS 0.02 0.05
Age 0.002 0.05 NS NS NS NS
Performance status 0.005 0.001 0.05 0.02 0.02 0.05
Ascites NS 0.05 NS NS NS NS
Adhesions NS 0.02 NS NS NS NS
CA125 NS 0.005 0.005 0.0005 0.0002 0.05
NS = not significant142 J. FISKEN et al.
Table III Primary disease characteristics ofpatients with CA125 assay after one cycle of primary chemotherapy. The
cohort were divided empirically into quartiles based upon their CA125 levels
No. patients in each quartile
Progressionfree survival Survival
Disease A B C D A B C D
characteristics (n = 10) (n = 10) (n = 9) (n = 9) (n = 15) (n = 14) (n = 14) (n = 14)
Mean age (years) 63 60.7 60.8 57.4 63.4 57.2 56.7 55.5
Median age (years) 67 60 61 58 67 56.5 60 53.6
Range (years 50-77 46-77 47-78 35-68 46-77 48-69 23-78 30-68
Stage III 8 8 6 6 12 12 9 11
Stage IV 2 2 3 3 3 2 5 3
Serous 9 6 4 6 12 10 9 11
Endometrioid - 3 2 3 1 3 2 3
PD adenocarcinoma 1 1 - - 2 1
Mucinous - - I - - I
Clear cell - - 1 I
Mixed - - 1 - - I1
Grade I 1 - - 3 1 3 4
Grade 2 4 - 2 - 4 - 3 1
Grade 3 5 10 7 6 10 14 8 9
Residual disease
<2cm 1 3 3 5 2 4 5 10
2-5 cm 3 2 4 4 4 3 6 4
>5cm 1 1 1 - 1 3 2
Bulky 5 4 - - 8 4 1 -
Performance status
0 5 2 3 1 7 5 7
1 4 3 5 3 6 5 7 4
2 4 1 5 1 1
3 2 2
Unknown - 2 1 3 1 1 1 3
Ascites 9 6 4 5 13 6 10 8
No ascites 1 4 5 4 2 8 4 6
Adhesion 10 8 10 9 15 12 12 10
No adhesions - 2 - 1 - 2 2 4
Table IV Primary treatment of patients in each quartile. The cohort were divided
empirically into quartiles based upon their CA125 levels
Group A Group B Group C Group D
Regime
Cisplatin/Prednimustine 5 (4) 5 (4) 8 (5) 7 (5)
Cisplatin/a-interferon -) 2 (1) I(-) (-)
Cisplatin (-) 3 (2) 2 (1) 3 (1)
Chlorambucil 10 (6) 1 (2) 4 (2) 2 (3)
5-Fluorouracil/Prednimustine/ (-) 3 (-) (1) 1 (-)
Hexamethylmelamine/cisplatin
Response
Complete response 1 (1) 4 (1) 4 (3) 10 (5)
Partial response 1 (1) 3 (2) 4 (2) 1 (1)
Stable disease 2 (1) 4 (2) 2 (2) (-)
Progressive disease 9 (7) 2 (4) 4 (2) 2 (3)
Not evaluable 2 (-) 1 (1) (-) 1 (-)
Reasonfor stopping treatment
Protocol complete 5 (3) 9 (3) 7 (4) 8 (4)
Toxicity 1 (1) 3 (3) 3 (3) 4 (2)
Refusal to complete 1 (-) (-) (-) (-)
Progressive disease 8 (6) 2 (4) 4 (2) 2 (3)
(X2 = 4.76, df= 1, P<0.05) and group C (X2 = 5.21, df= 1,
P<0.02).
Table V shows the range of CA125 values found in each
quartile. Two out of ten (20%) patients in group A were
progression free after 1 year, while 3/10 (30%), 4/9 (44.4%)
and 5/9 (55.5%) patients respectively in groups B, C and D
were progression free after 1 year. Patients in group A with
poor progression free survival had CAl25 levels >480 U
ml- , patients in groups B and C with intermediate progres-
sion free survival had CA125 levels ranging from 66-472 U
ml-', while patients in group D had good progression free
survival and CAl25 levels <63 U ml-' after one cycle of
chemotherapy (all but four patients in this group had normal
levels).
Prediction ofsurvival with CA125
Figure 2 shows the survival curves for each group. The
difference between the survival curves was significant
(x2 = 14.7, df = 3, P<0.005). Three prognostic groups,
group A with a very poor median survival of 7 months,
groups B and C with intermediate median survivals of 15 and
16 months respectively, and group D with a good median
survival of 23 months, can clearly be distinguished. PatientsTHE VALUE OF EARLY CA125 IN OVARIAN CANCER 143
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Figure 1 Progression free survival of patients according to CA125 levels after one cycle of primary chemotherapy. Patients in
group A (@) had a mean CA125 level of 1308 U ml-, patients in group B (A) had a mean CA125 level of 390 U ml ', patients in
group C (0) had a mean CA125 level of 150 Uml-', and those in group D (x) had a mean CA125 level of 39Uml-'. The
difference between the four survival curves was significant (X2 = 9.48, df= 3, P<0.02).
Table V CA125 levels in patients with poor, intermediate, and good progression free
survival
No. ofpatients
Median Progressionfree CA125 (U ml-')
Group n PFS at 12 months (%) mean median range
A - * 10 4.5 2/10 (20.0%) 1308 532 480-6183
B - A 10 8.5 3/10 (30.0%) 390 418.9 252-472
C - 0 9 12.0 4/9 (44.4%) 149.9 117.9 66.4-250.9
D - x 9 19.0 5/9 (55.5%) 39.2 35 6-62.9
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Figure 2 Survival of patients according to CA125 levels after one cycle of primary chemotherapy. Patients in group A (@) had a
mean CA125 level of 1109 Uml-', patients in group B (A) had a mean CA125 level of 340 Uml-', patients in group C (0) had a
mean CA125 level of 103 Uml-', and those in group D (x) had a mean CA125 level of 29 Uml-'. The difference between the
four survival curves was significant (X2 = 14.7, df = 3, P< 0.005).
in group A had a significantly poorer survival than patients
in group B (x2= 8.12, df= 1, P<0.005), group C (x2= 8.00,
df= 1, P<0.005), and group D (X2 = 13.91, df= 1, P<
0.001). There was no difference in survival between patients
in groups B and C. Patients in group D had significantly
better survival than those in groups A (x2 = 13.91, df = 1,
P<0.001), group B (X2= 6.67, df = 1, P<0.01) and group
C (X2 = 6.58, df = 1, P<0.02).
Table VI shows the range of CA125 levels found in each
group. Only 3/15 (20%) patients in group A with CA125
levels >451 Uml-' were alive at 1 year. Twenty-one out of
28 (75%) patients with CA125 levels in the range 58-
434 U ml-' (groups B and C) were alive at 1 year, while
13/14 (93%) patients in group D were alive at 1 year (all but
one patient in this group had normal levels).144 J. FISKEN et al.
Table VI CA125 levels in patients with poor, intermediate, and good survival
Median No. patients alive CA125 (Uml-1)
Group n survival at 12 months (%) mean median range
A - * 15 7 months 3/15 (20.0%) 1109 500 450-6183
B - A 14 15 months 10/14 (71.4%) 340 364 228-434
C - O 14 16 months 11/14 (78.6%) 103 102 58-221
D - x 15 23 months 13/14 (92.9%) 29 30 6-55
Discussion
CA125 in the immediate post-operative period was not a
significant predictor of either progression free or overall sur-
vival. These findings agree with Rustin et al. (1989). Redman
et al. (1990), however, found a significant difference in sur-
vival between seven patients with normal and 43 patients
with elevated post-operative CA125 levels. It is, however,
well known that surgical intervention causes a transient rise
in CA125 that may last for up to several weeks. In a recent
study, Van der Zee et al. (1990) found elevated post-
operative CA125 in 82% of patients, with normal pre-
operative levels, who underwent abdominal surgery for EOC,
cervical carcinoma or aortic disease. CA125 levels took 3 to 4
weeks to return to normal in their patients. 82% and 100%
of EOC patients debulked to <2 cm and >2 cm respectively
in our study had elevated CA125 levels within 1 to 4 weeks
after primary laparotomy (data not shown). Although post-
operative CA125 showed a highly significant correlation with
residual tumour burden in our study (data not shown), eleva-
tion of serum CA125 levels by surgical intervention may
partially explain the lack of prognostic value of CA125 at
this time.
After surgery, residual disease, age and performance status
were all significant predictors ofprogression free and overall
survival. Several authors, using Cox's proportional hazards
model for multivariate analysis, have reported a combination
of three or four independent prognostic factors. Bjorkholm et
al. (1982) found stage, age and histological type, Dembo and
Bush (1982) found residual disease, stage, age, and tumour
grade, Schray et al. (1983) found residual disease, age and
tumour grade to be independent predictors of survival in
EOC patients. None of these studies, however, took perfor-
mance status into consideration. A later, larger study by
Swenerton et al. (1985), that retrospectively assessed 16 char-
acteristics in 556 EOC patients found residual disease,
tumour grade and performance status to be independent
factors. They also reported prognostic factor variation with
stage; tumour grade was most important patients with stages
I and II, residual disease was most important in stage III,
and no other factor was more important than stage in
patients with stage IV disease. Dembo et al. (1990) also
found tumour grade to be the most important factor in
patients with early stage disease.
It was not possible to obtain progression dates for some
patients, however, similar prognostic factors were significant
in the prediction of both progression free and overall sur-
vival. This is not surprising as time to disease progression is
predictive of survival. Although the prognostic significance of
tumour grade has been consistently reported, it was not
significant in this study as the majority of patients had
poorly differentiated tumours. Recently, McGuire (1991) has
published a list ofguidelines for evaluating prognostic factors
in breast cancer patients. Patient-selection bias is a common
problem that may mask important factors, illustrated by the
lack of significance of tumour grade in this study. Small
sample size, a notorious cause of statistical insignificance in
randomised trials of chemotherapy regimes, is also a poten-
tial problem. Although the sample populations in this study
were small, the prognostic significance of residual disease,
performance status, age at diagnosis, and CA125 are fairly
consistent throughout primary treatment - emphasising the
importance of these factors. The above factors, with the
exception of performance status and CA125, are constant
and do not reflect the changing prognosis as a patient res-
ponds to further treatment.
CA125 was the most significant predictor of progression
free survival (P<0.0005) after the first cycle of chemo-
therapy, and was a highly significant predictor of survival
(P<0.005), although it did not add to performance status in
multivariate analysis. We were able to divide patients into
relatively good, intermediate and poor prognostic groups on
the basis of absolute CA125 levels after only one cycle of
primary chemotherapy; absolute CA125 measurement is less
complicated and time consuming than determination of
CA125 apparent half-life. It is also more precise.
Patients with CA125 levels <55 UmlhI had a median
survival of 23 months (all but one patient had normal levels),
patients with CA125 levels in the range 58-434 U ml-',
groups B and C, had median survivals of 15 and 16 months
respectively, and patients with CA125 levels >451 U ml'
had a median survival of 7 months. Whilst Redman et al.
(1990) and Sevelda et al. (1989) did not include performance
status in their survival assessments, CA125 did not add to
performance status in our study. Of the four patient groups,
those in group A with the highest CA125 levels also had at
least three other poor prognostic factors. The majority of
patients in group A had inoperable disease, poorly differ-
entiated tumours, and a performance status of two or three 1
month after primary surgery. All patients in group D with a
relatively good prognosis were optimally debulked and the
majority had a performance status of zero.
The majority of patients in group A had been treated with
chlorambucil because of advanced age and poor performance
status, while the majority of patients in the other groups
received more aggressive treatment - single agent cisplatinum
or combination cisplatinum-based regimes. While there were
fewer responses in patients in the poorest prognostic group
and most stopped chemotherapy because of disease progres-
sion, the majority ofpatients in other groups completed their
protocols. Given an accurate prognosis, treatment decisions
are still more likely to be influenced by patient desire for
active therapy (Cody & Slevin, 1989), by limitations of cur-
rent drug regimes, and increasingly by financial considera-
tions (Rees, 1990). When deciding whether to stop treatment
in patients with no change in markedly elevated CA125 levels
after one cycle of primary chemotherapy, Rustin (1991) has
urged caution in that up to 10% of patients may eventually
respond, and it would be wrong, he points out, to deny
patients this chance however slight. Such patients may have a
useful prolongation of progression free interval.
It is also worth considering that it is becoming increasingly
rare for patients to be reevaluated at the end of primary
chemotherapy with the prognostically informative second
look (Gershenson et al., 1985). Late on or at the end of
primary therapy therefore, CA125 estimation alone could be
a useful 'hard' prognostic indicator. A cost effective strategy
would be to assay CA125 after the first and then at the end
of a six cycle course of chemotherapy. If effective rescue
regimes or agents are developed there may be a case for more
frequent monitoring to permit early switching to an alterna-
tive therapy, such as taxol (Thigpen et al., 1990).
The case for or against including early serum CA125 in
prognostic evaluation of epithelial ovarian cancer to see
whether its usefulness changed with time and therapy would,
of course be greatly clarified by a suitable prospective study
in which some of the problems which beset retrospective
analyses, such as selection problems and incomplete collec-THE VALUE OF EARLY CAI25 IN OVARIAN CANCER 145
tion of data points, would be minimised. The initiation of
ICON 1 and ICON 2 provides an ideal opportunity to look
at CA125 prospectively in a large cohort of patients with
early and advanced EOC respectively (Williams, 1992).
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